FEATURE: Experts Question Value of Myriad s Proteome Mapping Strategy | GenomeWeb

NEW YORK, April 27 - Myriad Genetics made a splash earlier this month when it announced a collaboration with Hitachi and Oracle to "map the human proteome" by 2004.

The scope of this ambitious task could vary widely, depending on how the companies want to define "map" and how thorough they want to be. But regardless of how Myriad and its collaborators define the outer limits of the project, proteomics experts are questioning how much scientific value there is in Myriad's basic approach.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.